Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma

Advances in Hematology

Volumn 2012, Issue , 2012, Pages

  Martiniani, Roberta ^a   Di Loreto, Valentina ^a   Di Sano, Chiara ^a   Lombardo, Alessandra ^a   Liberati, Anna Marina ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 6; LENALIDOMIDE; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE REMODELING; CANCER CELL DESTRUCTION; CELL ADHESION; CELL EXPANSION; CELL PROLIFERATION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MECHANISM; GROWTH REGULATION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOSTIMULATION; MULTIPLE MYELOMA; NATURAL KILLER CELL; NATURAL KILLER T CELL; OSTEOCLASTOGENESIS; PLASMA CELL; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

EID: 84866173316     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2012/842945     Document Type: Review

References (98)

1. Corral L. G., Kaplan G., Immunomodulation by thalidomide and thalidomide analogues. Annals of the Rheumatic Diseases 1999 58 supplement 1 I107 I113 2-s2.0-0032726481
2. List A., Kurtin S., Roe D. J., Buresh A., Mahadevan D., Fuchs D., Rimsza L., Heaton R., Knight R., Zeldis J. B., Efficacy of lenalidomide in myelodysplastic syndromes. The New England Journal of Medicine 2005 352 6 549 557 2-s2.0-13444256401 10.1056/NEJMoa041668 (Pubitemid 40204668)
3. List A. F., Lenalidomide: from bench to bedside (part 1). Cancer Control 2006 13 supplement 2-3 2-s2.0-33846425712
4. List A. F., Baker A. F., Green S., Bellamy W., Lenalidomide: targeted anemia therapy for myelodysplastic syndromes. Cancer Control 2006 13 supplement 411 2-s2.0-33846449862
5. Raza A., Reeves J. A., Feldman E. J., Dewald G. W., Bennett J. M., Deeg H. J., Dreisbach L., Schiffer C. A., Stone R. M., Greenberg P. L., Curtin P. T., Klimek V. M., Shammo J. M., Thomas D., Knight R. D., Schmidt M., Wride K., Zeldis J. B., List A. F., Phase 2 study of lenalidomide in transfusion- dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008 111 1 86 93 2-s2.0-38049113182 10.1182/blood-2007-01-068833
6. List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E., Powell B., Greenberg P., Thomas D., Stone R., Reeder C., Wride K., Patin J., Schmidt M., Zeldis J., Knight R., Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. The New England Journal of Medicine 2006 355 14 1456 1465 2-s2.0-33749438404 10.1056/NEJMoa061292 (Pubitemid 44511560)
7. Tariman J. D., Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma. Clinical Journal of Oncology Nursing 2007 11 4 569 574 2-s2.0-35148899253
8. Weber D. M., Chen C., Niesvizky R., Wang M., Belch A., Stadtmauer E. A., Siegel D., Borrello I., Rajkumar S. V., Chanan-Khan A. A., Lonial S., Yu Z., Patin J., Olesnyckyj M., Zeldis J. B., Knight R. D., Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. The New England Journal of Medicine 2007 357 21 2133 2142 2-s2.0-36349010285 10.1056/NEJMoa070596 (Pubitemid 350146108)
9. Baz R., Walker E., Karam M. A., Choueiri T. K., Jawde R. A., Bruening K., Reed J., Faiman B., Ellis Y., Brand C., Srkalovic G., Andresen S., Knight R., Zeldis J., Hussein M. A., Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Annals of Oncology 2006 17 12 1766 1771 2-s2.0-33845350847 10.1093/annonc/mdl313 (Pubitemid 44884050)
10. Niesvizky R., Jayabalan D. S., Christos P. J., Furst J. R., Naib T., Ely S., Jalbrzikowski J., Pearse R. N., Zafar F., Pekle K., LaRow A., Lent R., Mark T., Cho H. J., Shore T., Tepler J., Harpel J., Schuster M. W., Mathew S., Leonard J. P., Mazumdar M., Chen-Kiang S., Coleman M., BiRD (Biaxin [clarithromycin]/revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008 111 3 1101 1109 2-s2.0-38949216066 10.1182/blood-2007-05-090258 (Pubitemid 351213388)
11. Rajkumar S. V., Hayman S., Nowakowski G. S., Dingli D., Gertz M. A., Dispenzieri A., Lacy M. Q., Fonseca R., Lust J. A., Kyle R. A., Greipp P. R., Witzig T. E., Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. Haematologica 2005 90 12 1650 1654 2-s2.0-29144480867 (Pubitemid 41814989)
12. Palumbo A., Falco P., Corradini P., Falcone A., Di Raimondo F., Giuliani N., Crippa C., Ciccone G., Omedè P., Ambrosini M. T., Gay F., Bringhen S., Musto P., Foà R., Knight R., Zeldis J. B., Boccadoro M., Petrucci M. T., Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMAItalian Multiple Myeloma Network. Journal of Clinical Oncology 2007 25 28 4459 4465 2-s2.0-35348923502 10.1200/JCO.2007.12. 3463 (Pubitemid 350063804)
13. Chanan-Khan A., Miller K. C., Musial L., Lawrence D., Padmanabhan S., Takeshita K., Porter C. W., Goodrich D. W., Bernstein Z. P., Wallace P., Spaner D., Mohr A., Byrne C., Hernandez-Ilizaliturri F., Chrystal C., Starostik P., Czuczman M. S., Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. Journal of Clinical Oncology 2006 24 34 5343 5349 2-s2.0-33947243663 10.1200/JCO.2005.05. 0401 (Pubitemid 46623164)
14. Chanan-Khan A., Porter C. W., Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncology 2006 7 6 480 488 2-s2.0-33744482623 10.1016/S1470-2045(06)70723-9 (Pubitemid 43796153)
15. Ramsay A. G., Johnson A. J., Lee A. M., Gorgün G., Dieu R. L., Blum W., Byrd J. C., Gribben J. G., Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. The Journal of Clinical Investigation 2008 118 7 2427 2437 2-s2.0-46749132717 10.1172/JC135017 (Pubitemid 351949771)
16. Ferrajoli A., Lee B. N., Schlette E. J., O'Brien S. M., Gao H., Wen S., Wierda W. G., Estrov Z., Faderl S., Cohen E. N., Li C., Reuben J. M., Keating M. J., Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008 111 11 5291 5297 2-s2.0-45949100928 10.1182/blood-2007-12-130120
17. Dispenzieri A., Lacy M. Q., Zeldenrust S. R., Hayman S. R., Kumar S. K., Geyer S. M., Lust J. A., Allred J. B., Witzig T. E., Rajkumar S. V., Greipp P. R., Russell S. J., Kabat B., Gertz M. A., The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007 109 2 465 470 2-s2.0-33846258025 10.1182/blood-2006-07-032987 (Pubitemid 46105939)
18. Gertz M. A., Comenzo R., Falk R. H., Fermand J. P., Hazenberg B. P., Hawkins P. N., Merlini G., Moreau P., Ronco P., Sanchorawala V., Sezer O., Solomon A., Grateau G., Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. American Journal of Hematology 2005 79 4 319 328 2-s2.0-23244448608 10.1002/ajh.20381 (Pubitemid 41098849)
19. Wiernik P. H., Lossos I. S., Tuscano J. M., Justice G., Vose J. M., Cole C. E., Lam W., McBride K., Wride K., Pietronigro D., Takeshita K., Ervin-Haynes A., Zeldis J. B., Habermann T. M., Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology 2008 26 30 4952 4957 2-s2.0-54449095901 10.1200/JCO.2007.15.3429
20. Tefferi A., Cortes J., Verstovsek S., Mesa R. A., Thomas D., Lasho T. L., Hogan W. J., Litzow M. R., Allred J. B., Jones D., Byrne C., Zeldis J. B., Ketterling R. P., McClure R. F., Giles F., Kantarjian H. M., Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006 108 4 1158 1164 2-s2.0-33747167338 10.1182/blood-2006-02-004572 (Pubitemid 44232010)
21. Treon S. P., Patterson C. J., Hunter Z. R., Branagan A. R., Phase II study of CC-5013 (revlimid) and rituximab in Waldenstrom's macroglobulinemia: preliminary safety and efficacy results. ASH Annual Meeting Abstracts 2005 106 11, abstract 2443
22. Chanan-Khan A. A., Cheson B. D., Lenalidomide for the treatment of B-cell malignancies. Journal of Clinical Oncology 2008 26 9 1544 1552 2-s2.0-41149168649 10.1200/JCO.2007.14.5367
23. Zangari M. T. G., Zeldis J., Eddlemon P., Saghafifar F., Barlogie B., Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT). Blood 2001 98, abstract 775a
24. Richardson P. G., Schlossman R. L., Weller E., Hideshima T., Mitsiades C., Davies F., Leblanc R., Catley L. P., Doss D., Kelly K., McKenney M., Mechlowicz J., Freeman A., Deocampo R., Rich R., Ryoo J. J., Chauhan D., Balinski K., Zeldis J., Anderson K. C., Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002 100 9 3063 3067 2-s2.0-0036839013 10.1182/blood-2002-03-0996 (Pubitemid 35217050)
25. Richardson P. G., Blood E., Mitsiades C. S., Jagannath S., Zeldenrust S. R., Alsina M., Schlossman R. L., Rajkumar S. V., Desikan K. R., Hideshima T., Munshi N. C., Kelly-Colson K., Doss D., McKenney M. L., Gorelik S., Warren D., Freeman A., Rich R., Wu A., Olesnyckyj M., Wride K., Dalton W. S., Zeldis J., Knight R., Weller E., Anderson K. C., A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006 108 10 3458 3464 2-s2.0-33750607347 10.1182/blood-2006-04-015909
26. Dimopoulos M., Spencer A., Attal M., Prince H. M., Harousseau J. L., Dmoszynska A., San Miguel J., Hellmann A., Facon T., Foà R., Corso A., Masliak Z., Olesnyckyj M., Yu Z., Patin J., Zeldis J. B., Knight R. D., Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. The New England Journal of Medicine 2007 357 21 2123 2132 2-s2.0-36349023319 10.1056/NEJMoa070594 (Pubitemid 350146107)
27. Dimopoulos M. A., Chen C., Spencer A., Niesvizky R., Attal M., Stadtmauer E. A., Petrucci M. T., Yu Z., Olesnyckyj M., Zeldis J. B., Knight R. D., Weber D. M., Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009 23 11 2147 2152 2-s2.0-70450230539 10.1038/leu.2009.147
28. Rajkumar S. V., Jacobus S., Callander N. S., Fonseca R., Vesole D. H., Williams M. E., Abonour R., Siegel D. S., Katz M., Greipp P. R., Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. The Lancet Oncology 2010 11 1 29 37 2-s2.0-73249146496 10.1016/S1470-2045(09)70284-0
29. Palumbo A., Cavallo F., Hardan I., A phase III study to compare melphalan, prednisone, lenalidomide (MPR) versus melphalan 200 mg/m2 and autologous transplantation (MEL200) in newly diagnosed multiple myeloma patients. Blood 2010 116, abstract 3573
30. Zonder J. A., Crowley J., Hussein M. A., Bolejack V., Moore D. F., Whittenberger B. F., Abidi M. H., Durie B. G. M., Barlogie B., Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 2010 116 26 5838 5841 2-s2.0-78649686431 10.1182/blood-2010-08-303487
31. Gay F., Rajkumar S. V., Coleman M., Kumar S., Mark T., Dispenzieri A., Pearse R., Gertz M. A., Leonard J., Lacy M. Q., Chen-Kiang S., Roy V., Jayabalan D. S., Lust J. A., Witzig T. E., Fonseca R., Kyle R. A., Greipp P. R., Stewart A. K., Niesvizky R., Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. American Journal of Hematology 2010 85 9 664 669 2-s2.0-77956457402 10.1002/ajh.21777
32. Richardson P. G., Weller E., Lonial S., Jakubowiak A. J., Jagannath S., Raje N. S., Avigan D. E., Xie W., Ghobrial I. M., Schlossman R. L., Mazumder A., Munshi N. C., Vesole D. H., Joyce R., Kaufman J. L., Doss D., Warren D. L., Lunde L. E., Kaster S., DeLaney C., Hideshima T., Mitsiades C. S., Knight R., Esseltine D. L., Anderson K. C., Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010 116 5 679 686 2-s2.0-77954618168 10.1182/blood-2010-02-268862
33. Knop S., Langer C., Engelhardt M., The efficacy and safety of RAD (lenalidomide, adriamycin and dexamethasone) in newly diagnosed multiple myelomafirst results of a phase II trial by the German DSMM Group. Blood 2010 116, abstract 1945
34. Kumar S. K., Flinn I., Noga S. J., Novel three-and four drug combination regimens of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for previously untreated multiple myeloma: results from the multicenter, randomized, phase 2 EVOLUTION Study. Blood 2010 116, abstract 621
35. Jakubowiak A. J., Reece D. E., Hofmeister C. C., Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: updated results of phase I/II MMRC trial. Blood 2009 114, abstract 132
36. Kuehl W. M., Bergsagel P. L., Multiple myeloma: evolving genetic events and host interactions. Nature Reviews Cancer 2002 2 3 175 187 2-s2.0-0036512435 (Pubitemid 37328787)
37. Hideshima T., Bergsagel P. L. I., Kuehl W. M., Anderson K. C., Advances in biology of multiple myeloma: clinical applications. Blood 2004 104 3 607 618 2-s2.0-3242777803 10.1182/blood-2004-01-0037 (Pubitemid 38970551)
38. Bergsagel P. L., Kuehl W. M., Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunological Reviews 2003 194 96 104 2-s2.0-0038675193 10.1034/j.1600-065X.2003.00052.x (Pubitemid 36886431)
39. Urashima M., Teoh G., Ogata A., Chauhan D., Treon S. P., Sugimoto Y., Kaihara C., Matsuzaki M., Hoshi Y., Decaprio J. A., Anderson K. C., Characterization of p16(INK4A) expression in multiple myeloma and plasma cell leukemia. Clinical Cancer Research 1997 3 11 2173 2179 2-s2.0-0030694727 (Pubitemid 27505148)
40. Guillerm G., Gyan E., Wolowiec D., Facon T., Avet-Loiseau H., Kuliczkowski K., Bauters F., Fenaux P., Quesnel B., p16INK4a and p15INK4b gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood 2001 98 1 244 246 2-s2.0-0035412365 10.1182/blood.V98.1.244
41. Kulkarni M. S., Daggett J. L., Bender T. P., Kuehl W. M., Bergsagel P. L., Williams M. E., Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis. Leukemia 2002 16 1 127 134 2-s2.0-0036153442 10.1038/sj/leu/2402328 (Pubitemid 34105608)
42. Teoh G., Anderson K. C., Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematology/Oncology Clinics of North America 1997 11 1 27 42 2-s2.0-0030889389 10.1016/S0889-8588(05)70413-5 (Pubitemid 27147744)
43. Hideshima T., Chauhan D., Hayashi T., Podar K., Akiyama M., Gupta D., Richardson P., Munshi N., Anderson K. C., The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Molecular Cancer Therapeutics 2002 1 7 539 544 2-s2.0-0036561859
44. Damiano J. S., Cress A. E., Hazlehurst L. A., Shtil A. A., Dalton W. S., Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999 93 5 1658 1667 2-s2.0-0033105537 (Pubitemid 29102494)
45. Hazlehurst L. A., Damiano J. S., Buyuksal I., Pledger W. J., Dalton W. S., Adhesion to fibronectin via β 1 integrins regulates p27(kip1) levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000 19 38 4319 4327 2-s2.0-0034618384
46. Chauhan D., Uchiyama H., Akbarali Y., Urashima M., Yamamoto K. I., Libermann T. A., Anderson K. C., Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF- κ B. Blood 1996 87 3 1104 1112 2-s2.0-0030041147 (Pubitemid 26043538)
47. Dankbar B., Padró T., Leo R., Feldmann B., Kropff M., Mesters R. M., Serve H., Berdel W. E., Kienast J., Vascular endothelial growth factor and interleukin-6 in paracrine tumor- stromal cell interactions in multiple myeloma. Blood 2000 95 8 2630 2636 2-s2.0-0034655957 (Pubitemid 30210543)
48. Gupta D., Treon S. P., Shima Y., Hideshima T., Podar K., Tai Y. T., Lin B., Lentzsch S., Davies F. E., Chauhan D., Schlossman R. L., Richardson P., Ralph P., Wu L., Payvandi F., Muller G., Stirling D. I., Anderson K. C., Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001 15 12 1950 1961 2-s2.0-0035195019 (Pubitemid 33115003)
49. Klein B., Zhang X. G., Jourdan M., Content J., Houssiau F., Aarden L., Piechaczyk M., Bataille R., Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989 73 2 517 526 2-s2.0-0024503249 (Pubitemid 19060538)
50. Hideshima T., Chauhan D., Schlossman R., Richardson P., Anderson K. C., The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001 20 33 4519 4527 2-s2.0-0035958517 10.1038/sj.onc.1204623 (Pubitemid 32772434)
51. Catlett-Falcone R., Landowski T. H., Oshiro M. M., Turkson J., Levitzki A., Savino R., Ciliberto G., Moscinski L., Fernández-Luna J. L., Nuez G., Dalton W. S., Jove R., Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999 10 1 105 115 2-s2.0-0032984589 10.1016/S1074-7613(00)80011-4 (Pubitemid 29077388)
52. Puthier D., Bataille R., Amiot M., IL-6 up-regulates mcl-1 in human myeloma cells through JAK / STAT rather than ras / MAP kinase pathway. European Journal of Immunology 1999 29 12 3945 3950
53. Jourdan M., Veyrune J. L., De Vos J., Redal N., Couderc G., Klein B., A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene 2003 22 19 2950 2959 2-s2.0-0038021146 10.1038/sj.onc.1206423 (Pubitemid 36648922)
54. Zhang B., Gojo I., Fenton R. G., Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002 99 6 1885 1893 2-s2.0-0037085778 10.1182/blood.V99.6.1885 (Pubitemid 34525465)
55. Verhelle D., Corral L. G., Wong K., Mueller J. H., Parseval L. M. D., Jensen-Pergakes K., Schafer P. H., Chen R., Glezer E., Ferguson G. D., Lopez-Girona A., Muller G. W., Brady H. A., Chan K. W. H., Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Research 2007 67 2 746 755 2-s2.0-33846665934 10.1158/0008-5472.CAN-06-2317 (Pubitemid 46192215)
56. Escoubet-Lozach L., Lin I. L., Jensen-Pergakes K., Brady H. A., Gandhi A. K., Schafer P. H., Muller G. W., Worland P. J., Chan K. W. H., Verhelle D., Pomalidomide and lenalidomide induce p21WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Research 2009 69 18 7347 7356 2-s2.0-70349739288 10.1158/0008-5472.CAN-08-4898
57. Gandhi A. K., Kang J., Capone L., Parton A., Wu L., Zhang L. H., Mendy D., Lopez-Girona A., Tran T., Sapinoso L., Fang W., Xu S., Hampton G., Bartlett J. B., Schafer P., Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Current Cancer Drug Targets 2010 10 2 155 167 2-s2.0-77950644007 10.2174/156800910791054239
58. Corral L. G., Haslett P. A., Muller G. W., Chen R., Wong L. M., Ocampo C. J., Patterson R. T., Stirling D. I., Kaplan G., Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF- α Journal of Immunology 1999 163 1 380 386 2-s2.0-0033168605 (Pubitemid 29295864)
59. Kotla V., Goel S., Nischal S., Heuck C., Vivek K., Das B., Verma A., Mechanism of action of lenalidomide in hematological malignancies. Journal of Hematology & Oncology 2009 2, article 36 2-s2.0-69949096727 10.1186/1756-8722-2-36
60. Xu J. L., Lai R., Kinoshita T., Nakashima N., Nagasaka T., Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. Journal of Clinical Pathology 2002 55 7 530 534 2-s2.0-0036066144 (Pubitemid 34779306)
61. Dredge K., Horsfall R., Robinson S. P., Zhang L. H., Lu L., Tang Y., Shirley M. A., Muller G., Schafer P., Stirling D., Dalgleish A. G., Bartlett J. B., Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvascular Research 2005 69 1-2 56 63 2-s2.0-20144375457 10.1016/j.mvr.2005. 01.002 (Pubitemid 40410468)
62. Chauhan D., Hideshima T., Anderson K. C., Apoptotic signaling in multiple myeloma: therapeutic implications. International Journal of Hematology 2003 78 2 114 120 2-s2.0-0041507093 (Pubitemid 37021950)
63. Dai Y., Dent P., Grant S., Tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) promotes mitochondrial dysfunction and apoptosis induced by 7-hydroxystaurosporine and mitogenactivated protein kinase kinase inhibitors in human leukemia cells that ectopically express Bcl-2 and Bcl-xL. Molecular Pharmacology 2003 64 6 1402 1409 2-s2.0-0346996812 10.1124/mol.64.6.1402 (Pubitemid 37532230)
64. Chauhan D., Hideshima T., Rosen S., Reed J. C., Kharbanda S., Anderson K. C., Apaf-1/cytochrome c independent and Smac dependent induction of apoptosis in multiple myeloma cells. The Journal of Biological Chemistry 2001 276 27 24453 24456 2-s2.0-0035816553 10.1074/jbc.C100074200
65. Chu Z. L., McKinsey T. A., Liu L., Gentry J. J., Malim M. H., Ballard D. W., Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF- κ B control. Proceedings of the National Academy of Sciences of the United States of America 1997 94 19 10057 10062 2-s2.0-0030885421 10.1073/pnas.94.19.10057 (Pubitemid 27406993)
66. Kreuz S., Siegmund D., Scheurich P., Wajant H., NF- κ B inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Molecular and Cellular Biology 2001 21 12 3964 3973 2-s2.0-0034744033 10.1128/MCB.21.12.3964-3973.2001 (Pubitemid 32476458)
67. Zou W., Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Reviews Cancer 2005 5 4 263 274 2-s2.0-16844379997 10.1038/nrc1586 (Pubitemid 40488632)
68. Urashima M., Ogata A., Chauhan D., Hatziyanni M., Vidriales M. B., Dedera D. A., Schlossman R. L., Anderson K. C., Transforming growth factor- β 1: differential effects on multiple myeloma versus normal B cells. Blood 1996 87 5 1928 1938 2-s2.0-0030026437 (Pubitemid 26068909)
69. Ogawara H., Handa H., Yamazaki T., Toda T., Yoshida K., Nishimoto N., Al-ma'Quol W. H. S., Kaneko Y., Matsushima T., Tsukamoto N., Nojima Y., Matsumoto M., Sawamura M., Murakami H., High Th1/Th2 ratio in patients with multiple myeloma. Leukemia Research 2005 29 2 135 140 2-s2.0-10644224388 10.1016/j.leukres.2004.06.003 (Pubitemid 39647506)
70. Maecker B., Anderson K. S., von Bergwelt-Baildon M. S., Weller E., Vonderheide R. H., Richardson P. G., Schlossman R. L., Menezes I. A., Xia Z., Munshi N. C., Anderson K. C., Nadler L. M., Schultze J. L., Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma. British Journal of Haematology 2003 121 6 842 848 2-s2.0-0038268128 10.1046/j.1365-2141.2003.04375.x (Pubitemid 36760302)
71. Dhodapkar M. V., Geller M. D., Chang D. H., Shimizu K., Fujii S. I., Dhodapkar K. M., Krasovsky J., A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. Journal of Experimental Medicine 2003 197 12 1667 1676 2-s2.0-0038543513 10.1084/jem.20021650 (Pubitemid 36745342)
72. Smyth M. J., Godfrey D. I., Trapani J. A., A fresh look at tumor immunosurveillance and immunotherapy. Nature Immunology 2001 2 4 293 299 2-s2.0-0035320526 10.1038/86297 (Pubitemid 33706339)
73. Jarahian M., Watzl C., Issa Y., Altevogt P., Momburg F., Blockade of natural killer cell-mediated lysis by NCAM140 expressed on tumor cells. International Journal of Cancer 2007 120 12 2625 2634 2-s2.0-34247507209 10.1002/ijc.22579 (Pubitemid 46651284)
74. Haslett P. A., Hanekom W. A., Muller G., Kaplan G., Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. Journal of Infectious Diseases 2003 187 6 946 955 2-s2.0-0037444106 10.1086/368126 (Pubitemid 36337907)
75. LeBlanc R., Hideshima T., Catley L. P., Shringarpure R., Burger R., Mitsiades N., Mitsiades C., Cheema P., Chauhan D., Richardson P. G., Anderson K. C., Munshi N. C., Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004 103 5 1787 1790 2-s2.0-10744231369 10.1182/blood-2003-02- 0361 (Pubitemid 38268973)
76. Brown R. D., Pope B., Murray A., Esdale W., Sze D. M., Gibson J., Joy Ho P., Hart D., Joshua D., Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor- β 1 and interleukin-10. Blood 2001 98 10 2992 2998 2-s2.0-0035892109 10.1182/blood.V98.10.2992
77. Ratta M., Fagnoni F., Curti A., Vescovini R., Sansoni P., Oliviero B., Fogli M., Ferri E., Cuna G. R. D., Tura S., Baccarani M., Lemoli R. M., Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002 100 1 230 237 2-s2.0-0036659945 10.1182/blood.V100.1. 230 (Pubitemid 35177452)
78. Gabrilovich D. I., Chen H. L., Girgis K. R., Cunningham H. T., Meny G. M., Nadaf S., Kavanaugh D., Carbone D. P., Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Medicine 1996 2 10 1096 1103 2-s2.0-0029842830 10.1038/nm1096-1096 (Pubitemid 26338628)
79. Schafer P. H., Gandhi A. K., Loveland M. A., Chen R. S., Man H. W., Schnetkamp P. P. M., Wolbring G., Govinda S., Corral L. G., Payvandi F., Muller G. W., Stirling D. I., Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. Journal of Pharmacology and Experimental Therapeutics 2003 305 3 1222 1232 2-s2.0-0038476461 10.1124/jpet.102.048496 (Pubitemid 36618002)
80. Hayashi T., Hideshima T., Akiyama M., Podar K., Yasui H., Raje N., Kumar S., Chauhan D., Treon S. P., Richardson P., Anderson K. C., Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. British Journal of Haematology 2005 128 2 192 203 2-s2.0-19944430437 10.1111/j.1365-2141.2004.05286.x
81. Bendelac A., Rivera M. N., Park S. H., Roark J. H., Mouse CD1-specific NK1 T cells: development, specificity, and function. Annual Review of Immunology 1997 15 535 562 2-s2.0-0030890603 10.1146/annurev.immunol.15.1.535 (Pubitemid 27169416)
82. Biron C. A., Nguyen K. B., Pien G. C., Cousens L. P., Salazar-Mather T. P., Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annual Review of Immunology 1999 17 189 220 2-s2.0-0033009888 10.1146/annurev.immunol.17.1.189 (Pubitemid 29241123)
83. Takeda K., Seid S., Ogasawara K., Anzai R., Hashimoto W., Sugiura K., Takahashi M., Satoh M., Kumagai K., Liver NK1.1+ CD4+ αβ T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. Journal of Immunology 1996 156 9 3366 3373 2-s2.0-0029966335
84. Cui J., Shin T., Kawano T., Sato H., Kondo E., Toura I., Kaneko Y., Koseki H., Kanno M., Taniguchi M., Requirement for V(α)14 NKT cells in IL-12-mediated rejection of tumors. Science 1997 278 5343 1623 1626 2-s2.0-0030613856 10.1126/science.278.5343.1623 (Pubitemid 27516281)
85. Trinchieri G., Scott P., Interleukin-12: a proinflammatory cytokine with immunoregulatory functions. Research in Immunology 1995 146 7-8 423 431 2-s2.0-0029557309 10.1016/0923-2494(96)83011-2
86. Fujii S., Shimizu K., Steinman R. M., Dhodapkar M. V., Detection and activation of human V α 24+ natural killer T cells using α -galactosyl ceramide-pulsed dendritic cells. Journal of Immunological Methods 2003 272 1-2 147 159 2-s2.0-0037437909 10.1016/S0022-1759(02)00497-0 (Pubitemid 36050752)
87. Carnaud C., Lee D., Donnars O., Park S. H., Beavis A., Koezuka Y., Bendelac A., Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. Journal of Immunology 1999 163 9 4647 4650 2-s2.0-0032729476 (Pubitemid 29501223)
88. Hayashi T., Hideshima T., Akiyama M., Podar K., Yasui H., Raje N., Kumar S., Chauhan D., Treon S. P., Richardson P., Anderson K. C., Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. British Journal of Haematology 2005 128 2 192 203 2-s2.0-19944430437 10.1111/j.1365-2141.2004.05286.x
89. Takahashi N., Maeda K., Ishihara A., Uehara S., Kobayashi Y., Regulatory mechanism of osteoclastogenesis by RANKL and Wnt signals. Frontiers in Bioscience 2011 16 1 21 30 2-s2.0-79954483045 10.2741/3673
90. Terpos E., Dimopoulos M. A., Sezer O., The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 2007 21 9 1875 1884 2-s2.0-34548128339 10.1038/sj.leu.2404843 (Pubitemid 47299959)
91. Breitkreutz I., Raab M. S., Vallet S., Hideshima T., Raje N., Mitsiades C., Chauhan D., Okawa Y., Munshi N. C., Richardson P. G., Anderson K. C., Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008 22 10 1925 1932 2-s2.0-54049124645 10.1038/leu.2008.216
92. Takumi I., Hiroshi H., Deciphering the mystery of thalidomide teratogenicity. Congenital Anomalies 2012 52 1 1 7
93. Zhu Y. X., Braggio E., Shi C. X., Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011 118 18 4771 4779
94. Chang X. B., Stewart A. K., What is the functional role of the thalidomide binding protein cereblon? International Journal of Biochemistry and Molecular Biology 2011 2 3 287 294
95. Cang Y., Zhang J., Nicholas S. A., Bastien J., Li B., Zhou P., Goff S. P., Deletion of DDB1 in mouse brain and lens leads to p53-dependent elimination of proliferating cells. Cell 2006 127 5 929 940 2-s2.0-33751331884 10.1016/j.cell.2006.09.045 (Pubitemid 44803064)
96. Cang Y., Zhang J., Nicholas S. A., Kim A. L., Zhou P., Goff S. P., DDB1 is essential for genomic stability in developing epidermis. Proceedings of the National Academy of Sciences of the United States of America 2007 104 8 2733 2737 2-s2.0-33847264495 10.1073/pnas.0611311104 (Pubitemid 46327948)
97. Lopez-Girona A., Mendy D., Miller K., Direct binding with cereblon mediates the antiproliferative and immunomodulatory action of lenalidomide and pomalidomide. Proceedings of the ASH Annual Meeting and Exposition 2011
98. Heintel D., Bolomsky A., Schreder M., High expression of the thalidomide-binding protein cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Proceedings of the ASH Annual Meeting and Exposition 2011